KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic): 2019-2024

Historic EPS (Basic) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$1.69.

  • Recursion Pharmaceuticals' EPS (Basic) fell 5.88% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 18.71%. This contributed to the annual value of -$1.69 for FY2024, which is 6.96% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported EPS (Basic) of -$1.69 as of FY2024, which was down 6.96% from -$1.58 recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' EPS (Basic) ranged from a high of -$1.36 in FY2022 and a low of -$3.99 during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median EPS (Basic) value was -$1.58 (recorded in 2023), while the average stood at -$1.54.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 39.02% in 2020, then spiked by 62.66% in 2021.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' EPS (Basic) stood at -$3.99 in 2020, then skyrocketed by 62.66% to -$1.49 in 2021, then increased by 8.72% to -$1.36 in 2022, then decreased by 16.18% to -$1.58 in 2023, then decreased by 6.96% to -$1.69 in 2024.